Clinical Trial Goal
To find out if linvoseltamab is safe and works well to treat high-risk MGUS and smoldering multiple myeloma
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following:
- MGUS that doctors consider high-risk
- Smoldering multiple myeloma
- Do not have any of the following:
- Smoldering multiple myeloma that doctors consider high-risk
- Systemic light-chain amyloidosis
- Waldenström macroglobulinemia
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Linvoseltamab is a bispecific antibody that targets BCMA on certain cells.
You’ll get:
You’ll get:
- Linvoseltamab – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 5.5 years.
The Food and Drug Administration (FDA) has approved linvoseltamab to treat multiple myeloma that has come back (relapsed) or not gotten better with treatment (refractory). Using it in this way to treat MGUS or smoldering multiple myeloma is new and unproven.
The Food and Drug Administration (FDA) has approved linvoseltamab to treat multiple myeloma that has come back (relapsed) or not gotten better with treatment (refractory). Using it in this way to treat MGUS or smoldering multiple myeloma is new and unproven.
Locations
Sponsors
lead: Regeneron Pharmaceuticals
